Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) Price Target at $5.20

Context Therapeutics Inc. (NASDAQ:CNTX) has earned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $5.20.

Several research analysts have weighed in on CNTX shares. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Thursday, October 16th. HC Wainwright dropped their target price on Context Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Guggenheim started coverage on Context Therapeutics in a research report on Thursday, September 18th. They issued a “buy” rating and a $5.00 target price on the stock. Cantor Fitzgerald started coverage on Context Therapeutics in a research report on Thursday, October 2nd. They issued an “overweight” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, October 8th.

Context Therapeutics Trading Down 3.5%

NASDAQ:CNTX opened at $1.09 on Wednesday. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.33. The business’s fifty day moving average price is $1.04 and its 200 day moving average price is $0.84. The firm has a market capitalization of $97.77 million, a price-to-earnings ratio of -3.03 and a beta of 1.93.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Equities analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Context Therapeutics stock. Clear Harbor Asset Management LLC increased its stake in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 60.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 92,804 shares of the company’s stock after acquiring an additional 35,000 shares during the period. Clear Harbor Asset Management LLC owned 0.10% of Context Therapeutics worth $90,000 as of its most recent filing with the SEC. 14.03% of the stock is currently owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.